SanBio Company Limited (4592.T)

419.00 +6.00 (+1.45%) 收市：03:15PM JST

SanBio Company Limited

St. Luke Tower
13th Floor 8-1 Akashi-cho Chuo-ku
Tokyo 104-0044
Japan
81 3 6264 3481
https://www.sanbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Toru Kawanishi	Co-Founder & Executive Chairman	無	無	1967
Mr. Keita Mori MBA	Co-Founder, President, Executive Officer, CEO & Representative Director	無	無	1967
Mr. Yoshihiro Kakutani	Corporate Officer of Management Administration	無	無	無
Mr. Greg Gillas	Senior Vice President of Human Resources & Corporate Services	無	無	無
Mr. Naoki Tsukahara	Senior Corporate Officer	無	無	無
Dr. Kazumi Sawaguchi Ph.D.	Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan	無	無	無
Mr. Keizo Nakada	Corporate Officer & Head of Production	無	無	無
Shinya Hirata	Corporate Officer & Head of Research and Development	無	無	無
Mr. Dai Chida	Senior Scientific Advisor	無	無	無
Masumi Akahori	In charge of IR	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 JPY。

描述

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

公司管治

截至 無 止，SanBio Company Limited 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。